Citius Pharmaceuticals, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 23.3K | $20.94K | 0.00% | Unchanged | 2026-03-31 |
| TwoSigma | quant | 13.1K | $11.82K | 0.00% | Trimmed-78.4% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-14upcoming | -0.36 | — | — |
| 2026-05-15 | -0.32 | -0.95 | -196.87% |
| 2026-02-13 | -0.30 | -0.38 | -26.67% |
| 2025-12-23 | -0.24 | -0.11 | +54.17% |
| 2025-08-12 | -0.21 | -0.80 | -280.95% |
| 2025-05-14 | 0.11 | -1.27 | -1254.55% |
| 2025-02-14 | -1.25 | -1.30 | -4.00% |
| 2024-12-27 | -1.53 | -5.80 | -279.91% |
| 2024-08-12 | -1.12 | -1.50 | -33.33% |
| 2024-05-14 | -1.50 | -1.25 | +16.67% |
| 2023-12-29 | -1.50 | -1.75 | -16.67% |
| 2023-08-14 | -1.75 | -1.50 | +14.29% |
| 2023-05-12 | -1.25 | -1.75 | -40.00% |
| 2022-12-22 | -1.50 | -1.25 | +16.67% |
| 2022-08-11 | -1.50 | -1.50 | — |
| 2022-05-12 | -1.75 | -1.25 | +28.57% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CTXR | -6.43% | -11.49% | -15.70% | -3.68% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -9.40% | -6.85% | -12.26% | -16.36% |